Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies.
Madariaga A, Sánchez-Bayona R, Kasherman L, Estrada-Lorenzo JM, Manso L, Tolosa P, Alva M, Lema L, González-Deza C, Ciruelos E, Valcarcel D, Lheureux S, Oza AM. Madariaga A, et al. Among authors: manso l. Int J Gynecol Cancer. 2024 Oct 8:ijgc-2024-005883. doi: 10.1136/ijgc-2024-005883. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39379328
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F. González-Martín A, et al. Among authors: manso l. J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668. Online ahead of print. J Clin Oncol. 2024. PMID: 39292975
High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer.
Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, Garcia-Saenz JÁ, Pernas S, Martinez Jañez N, Jiménez D, Adrover E, Andrés R, Mourón S, Bueno MJ, Manso L, Viñas G, Alba E, Llombart-Cussac A, Cortes J, Tebar C, Roe DJ, Grant A, Watson A, Colomer R, Mouneimne G. Quintela-Fandino M, et al. Among authors: manso l. Clin Cancer Res. 2024 Sep 16. doi: 10.1158/1078-0432.CCR-24-1518. Online ahead of print. Clin Cancer Res. 2024. PMID: 39283720
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.
Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Oaknin A, et al. Among authors: manso l. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11. Adv Ther. 2024. PMID: 39261417 Free PMC article. Clinical Trial.
SEOM-GEICO Clinical Guidelines on cervical cancer (2023).
Manso L, Ramchandani-Vaswani A, Romero I, Sánchez-Lorenzo L, Bermejo-Pérez MJ, Estévez-García P, Fariña-Madrid L, García García Y, Gil-Martin M, Quindós M. Manso L, et al. Clin Transl Oncol. 2024 Nov;26(11):2771-2782. doi: 10.1007/s12094-024-03604-3. Epub 2024 Aug 31. Clin Transl Oncol. 2024. PMID: 39215938 Free PMC article.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Among authors: manso l. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
Chrysin attenuates epithelial prostatic hyperplasia in the ventral prostate of spontaneously hypertensive rats.
Santos NRLD, de Sousa GC, Lima PN, Medeiros BCM, Manso LA, Silva CRB, Silveira CCRD, Ghedini PC, Campos HM, Costa MS, Fernandes IG, Mendes EP, Taboga SR, de Castro CH, Santos FCAD, Biancardi MF. Santos NRLD, et al. Among authors: manso la. Cell Biol Int. 2024 Oct;48(10):1533-1547. doi: 10.1002/cbin.12218. Epub 2024 Jul 11. Cell Biol Int. 2024. PMID: 38992896
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators. Vergote I, et al. Among authors: manso l. N Engl J Med. 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811. N Engl J Med. 2024. PMID: 38959480 Clinical Trial.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O'Shaughnessy J, Pivot X, Tolaney SM, Hurvitz SA, Llombart-Cussac A, André V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD. Goetz MP, et al. Among authors: manso lm. Ann Oncol. 2024 Aug;35(8):718-727. doi: 10.1016/j.annonc.2024.04.013. Epub 2024 May 8. Ann Oncol. 2024. PMID: 38729566 Free article. Clinical Trial.
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Sánchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, Alva M, Echavarria I, Moreno F, Tolosa P, Herrero Lopez B, de Luna A, Lema L, Gamez Casado S, Madariaga A, López-Tarruella S, Manso L, Bueno-Muiño C, Garcia-Saenz JA, Ciruelos E, Martin M. Sánchez-Bayona R, et al. Among authors: manso l. Breast Cancer Res Treat. 2024 Aug;206(3):551-559. doi: 10.1007/s10549-024-07324-8. Epub 2024 May 4. Breast Cancer Res Treat. 2024. PMID: 38703285
124 results